Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Approach to the patient with thrombocytosis

INTRODUCTION

The upper limit of the platelet count in normal adults differs among various sources and laboratories, but is generally accepted to be in the range of 350,000 to 450,000/microL (350 to 450 x 109 /L). As an example, in one study in 10,000 subjects, the 99th percentile for the platelet count was 409,000 and 381,000/microL, respectively, in women and men [1].

In this review, thrombocytosis will be arbitrarily defined as a platelet count greater than 450,000/microL, a value that has also been chosen by World Health Organization investigators as one of the criteria required for the diagnosis of essential thrombocythemia (table 1).

In any patient with newly recognized thrombocytosis, two questions should be addressed in a timely fashion:

Is the thrombocytosis a reactive phenomenon or a marker for the presence of a clonal (neoplastic, autonomous) hematologic disorder?

What is the immediate risk to the patient from the increased platelet count and how should it be managed?

                               

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2014. | This topic last updated: Aug 26, 2013.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Ruggeri M, Tosetto A, Frezzato M, Rodeghiero F. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. Ann Intern Med 2003; 139:470.
  2. Hollen CW, Henthorn J, Koziol JA, Burstein SA. Elevated serum interleukin-6 levels in patients with reactive thrombocytosis. Br J Haematol 1991; 79:286.
  3. Haznedaroğlu IC, Ertenli I, Ozcebe OI, et al. Megakaryocyte-related interleukins in reactive thrombocytosis versus autonomous thrombocythemia. Acta Haematol 1996; 95:107.
  4. Dan K, Gomi S, Inokuchi K, et al. Effects of interleukin-1 and tumor necrosis factor on megakaryocytopoiesis: mechanism of reactive thrombocytosis. Acta Haematol 1995; 93:67.
  5. Dame C, Sutor AH. Primary and secondary thrombocytosis in childhood. Br J Haematol 2005; 129:165.
  6. Taksin AL, Couedic JP, Dusanter-Fourt I, et al. Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L. Blood 1999; 93:125.
  7. Schafer AI. Thrombocytosis. N Engl J Med 2004; 350:1211.
  8. Yohannan MD, Higgy KE, al-Mashhadani SA, Santhosh-Kumar CR. Thrombocytosis. Etiologic analysis of 663 patients. Clin Pediatr (Phila) 1994; 33:340.
  9. Santhosh-Kumar CR, Yohannan MD, Higgy KE, al-Mashhadani SA. Thrombocytosis in adults: analysis of 777 patients. J Intern Med 1991; 229:493.
  10. Robbins G, Barnard DL. Thrombocytosis and microthrombocytosis: a clinical evaluation of 372 cases. Acta Haematol 1983; 70:175.
  11. Griesshammer M, Bangerter M, Sauer T, et al. Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J Intern Med 1999; 245:295.
  12. Tefferi A, Ho TC, Ahmann GJ, et al. Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis. Am J Med 1994; 97:374.
  13. Buss DH, Cashell AW, O'Connor ML, et al. Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. Am J Med 1994; 96:247.
  14. Heits F, Stahl M, Ludwig D, et al. Elevated serum thrombopoietin and interleukin-6 concentrations in thrombocytosis associated with inflammatory bowel disease. J Interferon Cytokine Res 1999; 19:757.
  15. Stone RL, Nick AM, McNeish IA, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012; 366:610.
  16. Chuncharunee S, Archararit N, Hathirat P, et al. Levels of serum interleukin-6 and tumor necrosis factor in postsplenectomized thalassemic patients. J Med Assoc Thai 1997; 80 Suppl 1:S86.
  17. Croese J, Harris O, Bain B. Coeliac disease. Haematological features, and delay in diagnosis. Med J Aust 1979; 2:335.
  18. Gertz MA, Kyle RA, Greipp PR. Hyposplenism in primary systemic amyloidosis. Ann Intern Med 1983; 98:475.
  19. Deray G, Lejonc JL, Galacteros F. Thrombocytosis as a feature of iron-deficiency therapeutic correction. Arch Intern Med 1984; 144:414.
  20. Ertenli I, Kiraz S, Oztürk MA, et al. Pathologic thrombopoiesis of rheumatoid arthritis. Rheumatol Int 2003; 23:49.
  21. Radley JM, Hodgson GS, Thean LE, et al. Increased megakaryocytes in the spleen during rebound thrombocytosis following 5-fluorouracil. Exp Hematol 1980; 8:1129.
  22. Haselager EM, Vreeken J. Rebound thrombocytosis after alcohol abuse: a possible factor in the pathogenesis of thromboembolic disease. Lancet 1977; 1:774.
  23. Johnson M, Gernsheimer T, Johansen K. Essential thrombocytosis: underemphasized cause of large-vessel thrombosis. J Vasc Surg 1995; 22:443.
  24. Kashuk JL, Moore EE, Johnson JL, et al. Progressive postinjury thrombocytosis is associated with thromboembolic complications. Surgery 2010; 148:667.
  25. Ho KM, Yip CB, Duff O. Reactive thrombocytosis and risk of subsequent venous thromboembolism: a cohort study. J Thromb Haemost 2012; 10:1768.
  26. Randi ML, Stocco F, Rossi C, et al. Thrombosis and hemorrhage in thrombocytosis: evaluation of a large cohort of patients (357 cases). J Med 1991; 22:213.
  27. Buss DH, Stuart JJ, Lipscomb GE. The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases. Am J Hematol 1985; 20:365.
  28. van Genderen PJ, Michiels JJ. Erythromelalgia: a pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 1997; 23:357.
  29. Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984; 64:1.
  30. Tefferi A. The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview. Mayo Clin Proc 1998; 73:1177.
  31. Tefferi A, Silverstein MN, Hoagland HC. Primary thrombocythemia. Semin Oncol 1995; 22:334.
  32. Harrison CN, Bareford D, Butt N, et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 2010; 149:352.
  33. Zandecki M, Dupriez B, Fenaux P, et al. Cytological and ultrastructural assessment of free crystals or precipitates associated with pseudoleukocytosis and pseudothrombocytosis in cryoglobulinemia. Nouv Rev Fr Hematol 1989; 31:397.
  34. Hutchinson CV, Stelfox P, Rees-Unwin KS. Needle-like cryoglobulin crystals presenting as spurious thrombocytosis. Br J Haematol 2006; 135:280.
  35. Ballard HS, Sidhu G. Cytoplasmic fragments causing spurious platelet counts in hairy cell leukemia: ultrastructural characterization. Arch Intern Med 1981; 141:942.
  36. Berkessy S. [Cytoplasm fragmentation of malignant lymphoma cells]. Folia Haematol Int Mag Klin Morphol Blutforsch 1983; 110:651.
  37. Lawrence C, Atac B. Hematologic changes in massive burn injury. Crit Care Med 1992; 20:1284.
  38. Alexandrakis MG, Passam FH, Moschandrea IA, et al. Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. Am J Clin Oncol 2003; 26:135.
  39. Ishiguro A, Suzuki Y, Mito M, et al. Elevation of serum thrombopoietin precedes thrombocytosis in acute infections. Br J Haematol 2002; 116:612.
  40. Español I, Hernández A, Cortés M, et al. Patients with thrombocytosis have normal or slightly elevated thrombopoietin levels. Haematologica 1999; 84:312.
  41. Messinezy M, Westwood N, Sawyer B, et al. Primary thrombocythaemia: a composite approach to diagnosis. Clin Lab Haematol 1994; 16:139.
  42. Uppenkamp M, Makarova E, Petrasch S, Brittinger G. Thrombopoietin serum concentration in patients with reactive and myeloproliferative thrombocytosis. Ann Hematol 1998; 77:217.
  43. Folman CC, Ooms M, Kuenen B B, et al. The role of thrombopoietin in post-operative thrombocytosis. Br J Haematol 2001; 114:126.
  44. Wang JC, Chen C, Novetsky AD, et al. Blood thrombopoietin levels in clonal thrombocytosis and reactive thrombocytosis. Am J Med 1998; 104:451.
  45. Hou M, Carneskog J, Mellqvist UH, et al. Impact of endogenous thrombopoietin levels on the differential diagnosis of essential thrombocythaemia and reactive thrombocytosis. Eur J Haematol 1998; 61:119.
  46. Cerutti A, Custodi P, Duranti M, et al. Thrombopoietin levels in patients with primary and reactive thrombocytosis. Br J Haematol 1997; 99:281.
  47. Osselaer JC, Jamart J, Scheiff JM. Platelet distribution width for differential diagnosis of thrombocytosis. Clin Chem 1997; 43:1072.
  48. Sehayek E, Ben-Yosef N, Modan M, et al. Platelet parameters and aggregation in essential and reactive thrombocytosis. Am J Clin Pathol 1988; 90:431.
  49. Okuma M. Thrombocytosis and thrombocythemia: qualitative platelet abnormalities. Nihon Ketsueki Gakkai Zasshi 1989; 52:1265.
  50. Gnatenko DV, Zhu W, Xu X, et al. Class prediction models of thrombocytosis using genetic biomarkers. Blood 2010; 115:7.
  51. Dewald GW, Wyatt WA, Juneau AL, et al. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood 1998; 91:3357.
  52. Patel K, Kelsey P. Primary acquired sideroblastic anemia, thrombocytosis, and trisomy 8. Ann Hematol 1997; 74:199.
  53. Bain BJ. The relationship between the myelodysplastic syndromes and the myeloproliferative disorders. Leuk Lymphoma 1999; 34:443.
  54. Shaw GR. Ringed sideroblasts with thrombocytosis: an uncommon mixed myelodysplastic/myeloproliferative disease of older adults. Br J Haematol 2005; 131:180.
  55. Vallespí T, Imbert M, Mecucci C, et al. Diagnosis, classification, and cytogenetics of myelodysplastic syndromes. Haematologica 1998; 83:258.
  56. Yamamoto K, Nagata K, Tsurukubo Y, et al. A novel translocation t(3;22)(q21;q11) involving 3q21 in myelodysplastic syndrome-derived overt leukemia with thrombocytosis. Leuk Res 2000; 24:453.
  57. Lavabre-Bertrand T, Bourquard P, Chiesa J, et al. Diabetes insipidus revealing acute myelogenous leukaemia with a high platelet count, monosomy 7 and abnormalities of chromosome 3: a new entity? Eur J Haematol 2001; 66:66.
  58. Keung YK, Buss D, Powell BL, Pettenati M. Central diabetes insipidus and inv(3)(q21q26) and monosomy 7 in acute myeloid leukemia. Cancer Genet Cytogenet 2002; 136:78.
  59. Rolovic Z, Basara N, Gotic M, et al. The determination of spontaneous megakaryocyte colony formation is an unequivocal test for discrimination between essential thrombocythaemia and reactive thrombocytosis. Br J Haematol 1995; 90:326.
  60. Juvonen E, Ikkala E, Oksanen K, Ruutu T. Megakaryocyte and erythroid colony formation in essential thrombocythaemia and reactive thrombocytosis: diagnostic value and correlation to complications. Br J Haematol 1993; 83:192.
  61. Yoon SY, Li CY, Tefferi A. Megakaryocyte c-Mpl expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: immunoperoxidase staining patterns and clinical correlates. Eur J Haematol 2000; 65:170.
  62. Mesa RA, Hanson CA, Li CY, et al. Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia. Blood 2002; 99:4131.
  63. Harrison CN, Gale RE, Pezella F, et al. Platelet c-mpl expression is dysregulated in patients with essential thrombocythaemia but this is not of diagnostic value. Br J Haematol 1999; 107:139.
  64. Li J, Xia Y, Kuter DJ. The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia. Br J Haematol 2000; 111:943.
  65. Hasegawa DK, Bennett AJ, Coccia PF, et al. Factor V deficiency in Philadelphia-positive chronic myelogenous leukemia. Blood 1980; 56:585.
  66. Budde U, van Genderen PJ. Acquired von Willebrand disease in patients with high platelet counts. Semin Thromb Hemost 1997; 23:425.
  67. Coon WW, Penner J, Clagett P, Eos N. Deep venous thrombosis and postsplenectomy thrombocytosis. Arch Surg 1978; 113:429.
  68. De Stefano V, Teofili L, Leone G, Michiels JJ. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost 1997; 23:411.
  69. Lengfelder E, Hochhaus A, Kronawitter U, et al. Should a platelet limit of 600 x 10(9)/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br J Haematol 1998; 100:15.
  70. Regev A, Stark P, Blickstein D, Lahav M. Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol 1997; 56:168.
  71. Low-dose aspirin in polycythaemia vera: a pilot study. Gruppo Italiano Studio Policitemia (GISP). Br J Haematol 1997; 97:453.